Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 29;63(2):e01671-18.
doi: 10.1128/AAC.01671-18. Print 2019 Feb.

Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model

Ziad Tarazi  1 , Mojgan Sabet  1 , Michael N Dudley  1 , David C Griffith  2
Affiliations

Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model

Ziad Tarazi et al. Antimicrob Agents Chemother. .

Abstract

Minocycline is currently approved in the United States for the treatment of infections caused by susceptible isolates of Acinetobacter spp. The objective of these studies was to determine the minocycline exposures associated with an antibacterial effect against Acinetobacter baumannii in a rat pneumonia model. Rats received minocycline doses as 30-min intravenous infusions. In the rat pneumonia model, six clinical isolates of A. baumannii with MICs ranging from 0.03 to 4 mg/liter were studied. In this model, minocycline produced a bacteriostatic effect with a free 24-h area under the concentration-time curve (AUC)/MIC ratio of 10 to 16 and produced 1 log of bacterial killing with a free 24-h AUC/MIC of 13 to 24. These exposures can be achieved with the current FDA-approved dosage regimens of intravenous minocycline.

Keywords: Acinetobacter baumannii; minocycline; pneumonia.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Pharmacokinetics of minocycline following a 30-min i.v. infusion in rats.
FIG 2
FIG 2
Relationship between exposure and response for minocycline against A. baumannii AB1148.
FIG 3
FIG 3
Relationship between exposure and response for minocycline against A. baumannii AB1036.
FIG 4
FIG 4
Relationship between exposure and response for minocycline against A. baumannii AB1016.
FIG 5
FIG 5
Relationship between exposure and response for minocycline against A. baumannii AB1161.
FIG 6
FIG 6
Relationship between exposure and response for minocycline against A. baumannii AB1157.
FIG 7
FIG 7
Relationship between exposure and response for minocycline against A. baumannii AB1129.
FIG 8
FIG 8
Relationship between exposure and response for minocycline against A. baumannii. Solid line, pooled results; orange circles, AB1148; red squares, AB1129; blue circles, AB1016; green triangles, AB1157; teal diamonds, AB1161; purple triangles, AB1036.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Camp C, Tatum OL. 2010. Review of Acinetobacter baumannii as a highly successful pathogen in times of war. Lab Med 41:6549–6657.
    1. Mendes RE, Farrell DJ, Sader HS, Jones RN. 2010. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn Microbiol Infect Dis 68:307–311. doi:10.1016/j.diagmicrobio.2010.07.003. - DOI - PubMed
    1. Karageorgopoulos DE, Falagas ME. 2008. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8:751–762. doi:10.1016/S1473-3099(08)70279-2. - DOI - PubMed
    1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. doi:10.1128/CMR.00058-07. - DOI - PMC - PubMed
    1. Bishburg E, Bishburg K. 2009. Minocycline—an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 34:395–401. doi:10.1016/j.ijantimicag.2009.06.021. - DOI - PubMed